Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ISHL HL Update 2021 | Personalized approaches to Hodgkin lymphoma

Alison Moskowitz • 19 Mar 2021
ISHL HL Update 2021
Hodgkin Lymphoma Lymphoma

Alison Moskowitz, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, touches on the importance of a personalized treatment approach in the management of Hodgkin lymphoma, as well as the identification of novel response biomarkers that can guide treatment strategies in this patient population. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.

More from Alison Moskowitz

A study of pembrolizumab maintenance as an alternative to autoSCT in R/R Hodgkin lymphoma 3:20
A study of pembrolizumab maintenance as an alternative to autoSCT in R/R Hodgkin lymphoma
Alison Moskowitz • 9 Dec 2024
Acimtamig with off-the-shelf allogeneic NK-cells in R/R cHL 1:44
Acimtamig with off-the-shelf allogeneic NK-cells in R/R cHL
Alison Moskowitz • 9 Dec 2024
A Phase Ib trial investigating the combination of ruxolitinib and duvelisib in R/R T-cell lymphoma 1:52
A Phase Ib trial investigating the combination of ruxolitinib and duvelisib in R/R T-cell lymphoma
Alison Moskowitz • 9 Dec 2024
Less aggressive approaches in relapsed/refractory Hodgkin lymphoma 2:50
Less aggressive approaches in relapsed/refractory Hodgkin lymphoma
Alison Moskowitz • 19 Mar 2021

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals